How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,471 results for

First Generation Sulfonylurea

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors

studies before adding more. Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03560323 Recruitment Status : Recruiting First Posted (...) /exercise, metformin monotherapy, sulfonylurea monotherapy (SU) or combination metformin/SU therapy. Masking: None (Open Label) Primary Purpose: Basic Science Official Title: SGLT2 Inhibitors, Ketones, & Cardiovascular Benefit Actual Study Start Date : January 7, 2019 Estimated Primary Completion Date : December 31, 2021 Estimated Study Completion Date : December 31, 2022 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment

2018 Clinical Trials

162. Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment

for details. ClinicalTrials.gov Identifier: NCT03637400 Recruitment Status : Not yet recruiting First Posted : August 20, 2018 Last Update Posted : August 20, 2018 See Sponsor: Los Angeles Biomedical Research Institute Collaborators: National Institute of Allergy and Infectious Diseases (NIAID) Washington University School of Medicine University of California, Los Angeles Information provided by (Responsible Party): loren g miller, Los Angeles Biomedical Research Institute Study Details Study Description (...) is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 9 Years to 85 Years (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age 9 years to 85 years Able to complete

2018 Clinical Trials

163. Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.

: Recruiting First Posted : August 20, 2018 Last Update Posted : August 31, 2018 See Sponsor: Massachusetts General Hospital Collaborators: Jawaharlal Nehru Medical College National Cancer Institute (NCI) Information provided by (Responsible Party): Tayyaba Hasan,Ph.D., Massachusetts General Hospital Study Details Study Description Go to Brief Summary: Oral cancer in India affects mostly those from the lower socioeconomic groups, due to a higher exposure to risk factors such as the use of tobacco, zarda (...) (NCI) Investigators Layout table for investigator information Principal Investigator: Tayyaba Hasan, PhD Massachusetts General Hospital, Boston More Information Go to Layout table for additonal information Responsible Party: Tayyaba Hasan,Ph.D., Professor of Dermatology, Massachusetts General Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: 2015P001855 First Posted: August 20, 2018 Last Update Posted: August 31, 2018 Last Verified: August 2018 Layout table for additional information

2018 Clinical Trials

164. A Study to Evaluate the Effect of add-on Pioglitazone or Glimepiride in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy

does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03499704 Recruitment Status : Not yet recruiting First Posted : April 17, 2018 Last Update Posted : January 17, 2019 See Sponsor: Takeda Information provided by (Responsible Party): Takeda Study Details Study Description Go to Brief Summary: The purpose of this study is to compare the efficacy (...) a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 19 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Has a historical diagnosis of type 2 diabetes. Has a body mass index (BMI) of approximately 20 to 30 kilogram per square meter (kg/m^2). Has been

2018 Clinical Trials

165. Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes

number of saved studies (100). Please remove one or more studies before adding more. Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03473262 Recruitment Status : Completed First (...) decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 80 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population The targeted population consists

2018 Clinical Trials

166. Use of Incretins in Diabetic Patients

a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Sampling Method: Probability Sample Study Population Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin Criteria Inclusion Criteria (...) of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03486964 Recruitment Status : Recruiting First Posted : April 3, 2018 Last Update Posted : April 3, 2018 See Sponsor: University of Pavia Information provided by (Responsible Party): Giuseppe Derosa, University

2018 Clinical Trials

167. A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: All Accepts Healthy Volunteers: No Sampling Method: Non-Probability Sample Study Population Participants diagnosed with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease over a 4-year period 1 April 2013 and 15 May 2017 will be observed. Criteria Inclusion Criteria: First (...) for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03492580 Recruitment Status : Completed First Posted : April 10, 2018 Last Update Posted : August 27, 2018 Sponsor: Janssen Research & Development, LLC

2018 Clinical Trials

168. A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Identifier: NCT03467932 Recruitment Status : Recruiting First Posted : March 16, 2018 Last Update Posted : February 27, 2019 See Sponsor: Oramed, Ltd. Collaborator: Integrium Information provided by (Responsible Party): Oramed, Ltd. Study Details Study Description Go to Brief Summary: This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks (...) glycemic levels and adverse events will be measured using self-monitored blood glucose (SMBG) and recorded in a diary. Treatment Period (Masking will be Participant, Care Provider, Investigator, Outcomes Assessor) Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Part 2: During Part 2, subjects will remain on fixed doses of ORMD-0801 or matched placebo for 10

2018 Clinical Trials

169. Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus

adding more. Effects of Dietary Fiber on Glucose Control in Subjects With Type 2 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03552991 Recruitment Status : Completed First Posted : June 12, 2018 Last Update Posted : June 12, 2018 Sponsor: Samsung Medical Center Collaborators (...) Intervention/treatment Agio arm It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes. Drug: Agiocur Pregranules 6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout Other Name: Agio gran. Outcome Measures Go to Primary Outcome

2018 Clinical Trials

170. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

of saved studies (100). Please remove one or more studies before adding more. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03591354 Recruitment Status : Enrolling by invitation First (...) and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 14 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Successful completion of the original 6-month RCT within the prior 14 days For females

2018 Clinical Trials

171. Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance

. Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03575000 Recruitment Status : Not yet recruiting First Posted : July 2, 2018 Last Update Posted : July 2 (...) psychiatrically stable APD-treated outpatients, at two sites (VA Pittsburgh and Stanford), aged 18 to 60 years old, with schizophrenia and comorbid IGT will be recruited and receive 6 weeks of bromocriptine (flexibly titrated, 2.5-5.0 mg PO daily). Key inclusion criteria are: 1) currently being treated with second generation APDs for 3 or more months with no change in dose in the 1 month prior to enrollment, 2) fasting glucose 100 to 125mg/dL and/or hemoglobin A1c (HbA1c) 5.7-6.4%. Key exclusions are: 1

2018 Clinical Trials

172. A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

for details. ClinicalTrials.gov Identifier: NCT03596177 Recruitment Status : Recruiting First Posted : July 23, 2018 Last Update Posted : March 15, 2019 See Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Study Description Go to Brief Summary: An Exploratory study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type II (...) members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 30 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Subjects aged ≥ 30 and ≤ 75 years at screening Provision of signed and dated written informed consent (except

2018 Clinical Trials

173. Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03640221 Recruitment Status : Not yet recruiting First Posted : August 21, 2018 Last Update Posted : August 24, 2018 See Sponsor: Cedars-Sinai Medical Center Collaborator: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Ron Victor, Cedars-Sinai Medical Center Study Details Study Description Go to Brief Summary: The sodium (...) to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 35 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of diabetes mellitus established < 24 months before enrollment Ages 30-65 years Men and women, inclusive or race/ethnic groups

2018 Clinical Trials

174. Effect of Different Weight Vests on Body Weight in Obese Individuals

Weight Vests on Body Weight in Obese Individuals (EVO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03672903 Recruitment Status : Active, not recruiting First Posted : September 17, 2018 Last Update Posted : February 28, 2019 Sponsor: Vastra Gotaland Region Collaborators: Claes Ohlsson, MD, PhD (...) . To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Obesity as defined by a BMI >30 and ≤35. Fat mass should be above 25 %. 18-70 years of age. We will primarily recruit men. Women will only be recruited if we

2018 Clinical Trials

175. Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

. Subjects should be on stable and maximally tolerated doses throughout the study unless sulfonylureas require adjustment to reduce the risk of hypoglycemia during the study. Subjects who are otherwise in generally satisfactory health. Likely to follow study requirements, in particular, to adhere to maintaining a suitable diet and keeping an online diary of their food intake and weight measured once weekly via EDC. Female subjects have negative urine pregnancy test at the Screening visit. Provides signed (...) studies before adding more. Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03655535 Recruitment Status : Recruiting First Posted

2018 Clinical Trials

176. Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revitaâ„¢ System in Treatment of Type 2 Diabetes

. ClinicalTrials.gov Identifier: NCT03653091 Recruitment Status : Recruiting First Posted : August 31, 2018 Last Update Posted : March 19, 2019 See Sponsor: Fractyl Laboratories, Inc. Information provided by (Responsible Party): Fractyl Laboratories, Inc. Study Details Study Description Go to Brief Summary: The Revita™ System is being investigated to assess the ability to improve glycemic control in conjunction with diet and exercise in patients with Type 2 diabetes who are inadequately controlled with oral anti (...) over a guide-wire to first inject saline to lift the sub‐mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study. Sham Comparator: Duodenal Mucosal Resurfacing Sham (Sham) Duodenal Mucosal Resurfacing Sham (Sham) treatment

2018 Clinical Trials

177. Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)

of GLP-1 Agonist on Liver STeatosis (REALIST) (REALIST) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03648554 Recruitment Status : Not yet recruiting First Posted : August 27, 2018 Last Update Posted : August 27, 2018 (...) by liver puncture biopsy Score > 4 = NASH confirmed Score 3-4 = borderline Score < 3 = absence of NASH Secondary Outcome Measures : Fibrosis METAVIR score [ Time Frame: after 52 weeks of treatment ] Mean changes in Fibrosis METAVIR score. It combines two numbers: the first identified by the letter A (activity) is graded from 0 to 3. It reflects the activity of hepatitis (inflammation and necrosis). The second identified by the letter F (fibrosis) characterizes fibrous lesions already existing

2018 Clinical Trials

178. Open Randomized Clinical Trial to Evaluate the Effects of Intermittent Caloric Restriction in Patients With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03669692 Recruitment Status : Recruiting First Posted : September 13, 2018 Last Update Posted : September 21, 2018 See Sponsor: Complexo Hospitalario Universitario de A Coruña Information provided by (Responsible Party): José Luis Ponce Díaz-Reixa, Complexo Hospitalario Universitario de (...) or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 45 Years and older (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Signature of specific informed consent for this study. Metabolic syndrome according to WHO criteria Current intake food pattern > 14 hours of duration. Total PSA below 2,5 ng/mL or total PSA 4 - 10

2018 Clinical Trials

179. Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses

studies before adding more. Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03648424 Recruitment Status : Active, not recruiting First Posted : August 27, 2018 Last Update Posted : August 27, 2018 Sponsor: Brigham (...) Glimepiride in Type 2 Diabetes (CAROLINA) is an ongoing randomized controlled trial (RCT) designed to assess whether linagliptin is non-inferior, and if so, superior compared with glimepiride 1-4 mg once daily with respect to cardiovascular (CV) events in adults with relatively early Type 2 Diabetes at increased risk of CV events and with less than optimized glycaemic control. Given that medications of both classes are currently advocated as second-line therapy after metformin, and since sulfonylureas

2018 Clinical Trials

180. The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System

. The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03674281 Recruitment Status : Recruiting First Posted : September 17, 2018 Last Update Posted (...) will evaluate up to 15 subjects in each age group for a period of 8-10 weeks performing neurocognitive tests before and after each intervention. The first study phase will be up to 2 weeks of a training period to allow participants to get acquainted with the use of the CGM if they are not familiar with the use of the device. This training period will be followed by a 4-week sensor-augmented pump (SAP) period using a study CGM and the subject's personal insulin pump. The subjects will return to clinic

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>